{
    "clinical_study": {
        "@rank": "13413", 
        "arm_group": [
            {
                "arm_group_label": "13-valent peumococcal conjugate vaccine(13vPnC)", 
                "arm_group_type": "Experimental", 
                "description": "Participants aged over 50 years are given a 0.5mL dose administered on day 0."
            }, 
            {
                "arm_group_label": "23-valent peumococcal Polysaccharide Vaccine(23vPS)", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants aged over 50 years are given a 0.5mL dose administered on day 0."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the Immunogenicity and safety of 13-valent Pneumococcal Conjugate\n      Vaccine compared with 23-valent Pneumococcal Polysaccharide Vaccine. All participants should\n      be na\u00efve of Pneumococcal vaccine."
        }, 
        "brief_title": "Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine", 
        "condition": "Pneumococcal Infections", 
        "condition_browse": {
            "mesh_term": "Pneumococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Male and Female adults over 50 years of age at time of enrollment.\n\n          -  The subject able and willing to comply with all stuy procedures.\n\n          -  If the subject is female, she must be of non-childbearing potential, i.e., either\n             surgically sterilized or 2 years post-menopausal\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to any components of the pneumococcal conjugate vaccine\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient conditions including\n             leukemia, multiple myeloma, lympoma, Hodgkin's disease, etc.\n\n          -  History of autoimmune disease including multiple sclerosis(MS), lupus, polymyositis,\n             dermatomyositis, Hashmoto's thyroiditis, Sjogren's syndrome, rheumatoid arthritis\n\n          -  Functional or anatomic asplenia\n\n          -  Coagulation disorder contraindicating IM vaccination\n\n          -  Use of any immunosuppressive therapies within the preceding 3 months including\n             anti-cancer chemotherapies or radiation therapies and medication such as\n             cyclophosphamide, 6-mercaptourine, azathioprine, methotrexate, steroids, cyclosporine\n             A, rapamycin, leflunomide, TNF-\u03b1 antagonist (For corticosteroids, this will mean\n             prednisone, or equivalent dose of \u2265 15mg/day. Inhaled and topical steroids are\n             allowed.)\n\n          -  Serious chronic disorders including metastatic malignancy, severe chronic obstructive\n             pulmonary disease requiring supplemental oxygen, end-stage renal disease with or\n             without dialysis, clinically unstable cardiac disease, impaired immune function.\n\n          -  Any licensed vaccine administered within the 1 month prior to receipt of study\n             vaccine or is scheduled to receive any other licensed vaccine within 1 month\n             following receipt of study vaccine.\n\n          -  Subject has received diphtheria toxoid within 6 months prior to receipt of study\n             vaccine or planned to receive diphtheria toxoid during full period of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079207", 
            "org_study_id": "NPB606_PCVA_III_2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "23-valent peumococcal Polysaccharide Vaccine(23vPS)", 
                "intervention_name": "13-valent peumococcal conjugate vaccine(13vPnC)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "13-valent peumococcal conjugate vaccine(13vPnC)", 
                "intervention_name": "23-valent peumococcal Polysaccharide Vaccine(23vPS)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 3, 2014", 
        "number_of_arms": "2", 
        "official_title": "Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are na\u00efve to Pneumococcal Vaccine", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "MYUNGDON OH, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For the comparison of OPA GMTs elicited by NBP606 relative to Prodiax-23, the 2-sided 95% CI on the geometric mean ratio(GMR) for each serotype is calculated.", 
            "measure": "Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month(Day 28) After Vaccination 1", 
            "safety_issue": "No", 
            "time_frame": "One month after vaccination 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079207"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "For the comparison of IgG GMC elicited by NBP606 relative to Prodiax-23, the 2-sided 95% CI on the geometric mean ratio(GMR) for each serotype is calculated.", 
            "measure": "Serotype-specific immunoglobulin(IgG) Geometric Mean Concentration (GMC) 1 Month(Day 28) After Vaccination 1", 
            "safety_issue": "No", 
            "time_frame": "One Month After Vaccination 1"
        }, 
        "source": "SK Chemicals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SK Chemicals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}